Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology. - Mercuri FA; White S; McQuilten HA; Lemech C; Mynhardt S; Hari R; Zhang P; Kruger N; McLachlan G; Miller BE; West NP; Tal-Singer R; et al. (ERJ open research, 2024)